Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

Vaccines

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...

Vaccinations

Vaccinations

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Lipidomic profiling of extracellular vesicles from breast and metastatic triple-negative breast cancer cell lines for identification of potential biomarkers.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2026

Same author

Fully synthetic, nature-inspired exosome-mimetics for melanoma therapy.

International journal of pharmaceutics·2026

Same author

Preliminary results on novel adjuvant combinations suggest enhanced immunogenicity of whole inactivated pandemic influenza vaccines.

Frontiers in drug delivery·2025

Same author

Corrigendum: Preliminary results on novel adjuvant combinations suggest enhancement immunogenicity of whole inactivated pandemic influenza vaccines.

Frontiers in drug delivery·2025

Same author

Liposomal Tubacin: Strategies for the Formulation of a Highly Hydrophobic Anticancer Drug.

Pharmaceutics·2025

Same author

When conventional approach in toxicity assays falls short for nanomedicines: a case study with nanoemulsions.

Drug delivery and translational research·2025

Search research articles

Related Experiment Video

Updated: May 12, 2026

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle (VLP)-Based Vaccines Using a Capture Assay

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle (VLP)-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

Recent advances in mucosal immunization using virus-like particles.

Gaëlle Vacher¹, Matthias D Kaeser, Christian Moser

¹School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, 1211 Geneva, Switzerland.

Molecular Pharmaceutics

|April 4, 2013

Summary

Virus-like particles (VLPs) show promise for mucosal vaccines, offering systemic and mucosal immunity with better patient compliance. Further research is needed to overcome obstacles for broader clinical application.

More Related Videos

Expression and Purification of Virus-like Particles for Vaccination

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

Related Experiment Videos

Last Updated: May 12, 2026

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle (VLP)-Based Vaccines Using a Capture Assay

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle (VLP)-Based Vaccines Using a Capture Assay

Published on: February 10, 2022

Expression and Purification of Virus-like Particles for Vaccination

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

A "Plug-And-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-Binding Domain

Published on: July 25, 2022

Area of Science:

Immunology
Vaccinology
Biotechnology

Background:

Mucosal immunization elicits both systemic and mucosal immune responses, improving patient compliance.
Defined antigens like proteins and peptides require effective delivery systems for strong immunogenicity and safety.
Virus-like particles (VLPs) mimic natural pathogens, offering antigen protection and immune stimulation.

Purpose of the Study:

To review the potential and challenges of virus-like particles (VLPs) for mucosal immunization.
To identify strategies for enhancing VLP immunogenicity and safety for clinical use.

Main Methods:

Literature review of preclinical and clinical studies on VLP-based mucosal vaccines.
Analysis of VLP structure, function, and immune response induction.
Evaluation of safety and tolerability profiles of VLPs in immunization.

Main Results:

VLPs demonstrate significant potential for mucosal vaccination due to their pathogen-mimicking structure and inherent adjuvant properties.
Preclinical studies show promising immunogenicity, but clinical translation remains limited.
Challenges include optimizing VLP design for specific mucosal sites and ensuring long-term safety.

Conclusions:

VLPs offer a promising platform for developing next-generation mucosal vaccines.
Overcoming current obstacles requires further research into VLP engineering and clinical evaluation.
Balancing immunogenicity with safety is crucial for successful VLP-based mucosal immunization.